3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
26
Nivolumab
10
Docetaxel
8
avelumab
7
atezolizumab
7
Gemcitabine
7
Carboplatin
6
Trastuzumab
5
Ipilimumab
5
Radiosurgery
4
Psychiatric Rehabilitation
4
Immunoglobulin G
4
Early Intervention, Educational
4
Cyclophosphamide
4
fludarabine
3
durvalumab
3
cemiplimab
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Disulfides
3
Counseling
3
Cisplatin
3
Blood Specimen Collection
3
Biopsy
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
zimberelimab
2
utomilumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
AZD5305
×
Thoracic
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled